医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpineGuard Obtains Regulatory Clearance to Sell PediGuard® in the World’s Second-Largest Spine Market: China

2015年07月01日 AM01:00
このエントリーをはてなブックマークに追加


 

PARIS & SAN FRANCISCO

SpineGuard (FR0011464452 – ALSGD) announced today that it has received regulatory clearance to market its Classic PediGuard® products in China.

This regulatory clearance is the result of a diligent collaborative process with General Care International (GCI),” said Pierre Jérôme, Co-founder and Chief Executive Officer of SpineGuard. “It is a major milestone for SpineGuard and further validates the value of our DSG™ (Dynamic Surgical Guidance)-based PediGuard device for making spine surgery safer.

The China spine market has become the second-largest market in spine after the USA and is projected to be worth over $1 billion by 2019 according to IData Research, driven by an ageing population, increasing disease, improving treatment rate and growing affordability. “The number of spine fusions is growing rapidly across China, and I believe there is a strong need for a simple smart device like PediGuard consistently ensuring safe and accurate placement of pedicle screws,” added Professor Yong Qiu, Chief Spinal Surgeon at the Nanjing University Hospital.

About SpineGuard®

Co-founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard’s mission is to make spine surgery safer. Its primary objective is to establish its proprietary Dynamic Surgical Guidance (DSG™) technology as the global standard of surgical care, initially for safer screw placement in spine surgery and then in other surgeries. PediGuard®, the first device designed using DSG was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Close to 40,000 surgical procedures have been performed worldwide with PediGuard. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard delivers to patients, surgical staff and hospitals. In 2015 SpineGuard started to expand the applications of DSG into pedicle screws through partnerships with innovative surgical companies in France and the US. SpineGuard has offices in San Francisco and Paris. For further information, visit www.spineguard.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150630005928/en/

CONTACT

SpineGuard
Pierre Jérôme, +33 (0)1 45 18 45 19
Chief
Executive Officer
p.jerome@spineguard.com
or
Manuel
Lanfossi
Chief Financial Officer
m.lanfossi@spineguard.com
or
Europe
/ NewCap

Investor Relations & Financial Communication
Florent
Alba / Pierre Laurent, +33 (0)1 44 71 94 94
spineguard@newcap.fr
or
US
Ronald
Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表